Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne

Treatments

Sarepta Therapeutics announces positive results from the ESSENCE study
By Marie
In News, Research, Treatments
Posted 28 March 2019

Sarepta Therapeutics announces positive results from the ESSENCE study

Sarepta Therapeutics, Inc., a leader in precision genetic medicine for rare diseases, announced positive results from its interim analysis of muscle biopsy endpoints comparing casimersen [...]

Idebenone for Duchenne muscular dystrophy
By Marie
In Research, Treatments
Posted 1 March 2019

Idebenone for Duchenne muscular dystrophy

February 25, 2019 Santhera Pharmaceuticals announces results from the SYROS study.   The primary objective of this study was to evaluate the long-term evolution of the respiratory function [...]

New drug for DMD being reviewed by the FDA
By Marie
In News, Research, Treatments
Posted 15 February 2019

New drug for DMD being reviewed by the FDA

Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 Press release here: Sarepta.com   [...]

Patient registry demonstrating Translarna™ slows DMD progression
By Marie
In News, Treatments
Posted 9 October 2018

Patient registry demonstrating Translarna™ slows DMD progression

Here’s the latest news from PTC Therapeutics about Translarna™ (ataluren). In a recent press release, PTC announces that Translarna™ (ataluren) slows disease progression in children with Duchenne [...]

Deflazacort over prednisone/prednisolone?
By Marie
In News, Treatments
Posted 26 July 2018

Deflazacort over prednisone/prednisolone?

Here’s the latest news from PTC Therapeutics about Deflazacort (EMFLAZA®). A publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and [...]

Negative opinion for EXONDYS® in Europe
By Marie
In News, Treatments
Posted 21 June 2018

Negative opinion for EXONDYS® in Europe

  Here’s the latest news from Sarepta Therapeutics press release about EXONDYS® (eteplirsen). EXONDYS® (eteplirsen) is designed to treat patients with Duchenne muscular dystrophy (DMD) [...]

Positive news for Translarna™ (ataluren)
By Marie
In News, Treatments
Posted 12 June 2018

Positive news for Translarna™ (ataluren)

  One of the objectives of our team is to inform you about new treatments. Here’s the latest news from PTC Therapeutics press release about Translarna ™ (ataluren). Enjoy reading and [...]

Recruiting participants here in Canada
By Marie
In News, Treatments
Posted 7 June 2018

Recruiting participants here in Canada

  Sarepta Therapeutics is recruiting DMD patients that have out-of-frame deletion mutations in dystrophin that may be treated by skipping exon 45 or exon 53 for its ESSENCE study.   [...]

New DMD exon-skipping therapy on the way
By Marie
In News, Research, Treatments
Posted 22 March 2018

New DMD exon-skipping therapy on the way

Following positive results obtained in Phase I/II trial of SRP-4053 (Golodirsen), Sarepta Therapeutics has announced a plan to submit a new drug application (NDA) for accelerated approval of [...]

Canadian Research osteoprotegerin (OPG)
By La Force DMD
In Research, Treatments
Posted 10 March 2018

Canadian Research osteoprotegerin (OPG)

Meeting with professor Jérôme Frenette about osteoprotegerin (OPG). We are producing a video series of interviews with Canadian researchers working on DMD. We have met many professors, and our [...]

1 2 3 4 5
page 1 of 5

Articles récents

  • The global day of giving
  • EMBARK, gene therapy for the treatment of DMD
  • Part B of MOMENTUM study of SRP-5051 in patients with DMD
  • World Duchenne Awareness Day 2021
  • ENDEAVOR, gene therapy for DMD

Catégories

  • Fundraising
  • in the Medias
  • News
  • Research
  • Testimonial
  • Treatments

+

Restez informé

    LA Force - Dystrophie musculaire de Duchenne

    La Force dmd - Tous droits réservés - Organisme de bienfaisance enregistré : 817683568RP0001
    La Force dmd La Force dmd
    • S’informer
      • Frequently Asked Questions
    • Make a Donation
    • Agir
      • Quick guige – Management of DMD
      • Take action – What’s your genetic profile?
      • Take action – Subscribe to registries
    • Aller plus loin
      • Go further – How can you access a new treatment?
      • Go further – How do researchers test new treatments?
      • Go further – How are drugs approved for use in Canada?
      • Go further – Who decides to reimburse drug costs?
    • Blog
    • About us
    • Contact-us
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistiques
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}